文献速递类风湿关节炎

法国类风湿关节炎管理欠佳:基于法国国家健康数据系统的真实世界研究

Suboptimal management of rheumatoid arthritis in France: a real-world study based on data from the French National Health Data System.
PubMed 文献 · RMD Open · 2023-01-01

基于法国国家健康数据系统样本库的纵向研究,纳入2013至2017年2553例类风湿关节炎患者,描述治疗模式、持续性与依从性。2017年近半数患者未接受改善病情抗风湿药治疗,多数使用对症治疗,近半数改善病情抗风湿药起始伴随长期高剂量口服激素使用。

要点

  • 2017年2315例患者中47.6%未接受改善病情抗风湿药治疗。
  • 85.7%接受对症治疗,包括镇痛药81.0%、激素49.2%、非甾体抗炎药39.5%。
  • 近半数改善病情抗风湿药起始伴随长期(>6个月)高剂量口服激素(约7 mg/天泼尼松等效)。

核心结论

  • 尽管治疗手段多样,当前类风湿关节炎管理仍存在未被满足的医疗需求,常通过过度处方激素来补偿。

研究设计与样本

  • 纵向研究,使用法国永久代表性样本(Echantillon Généraliste des Bénéficiaires)理赔数据库,纳入2013至2017年识别的2553例类风湿关节炎患者,描述治疗模式、持续性和依从性。

主要发现

  • 2553例患者中1512例(59.2%)被处方改善病情抗风湿药,其中721例(47.6%)无需停药或换药。
  • 377例(24.9%)停药,114例(7.5%)换用靶向改善病情抗风湿药(生物制剂和合成(Janus激酶抑制剂)改善病情抗风湿药)。
  • 2017年2315例患者中近半数(n=1102,47.6%)未接受改善病情抗风湿药治疗。
  • 多数(85.7%)接受对症治疗:镇痛药81.0%、激素49.2%、非甾体抗炎药39.5%。
  • 1142次治疗起始中713次(62.4%)为传统合成改善病情抗风湿药,甲氨蝶呤最常见(n=553,48.45%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The emergence of targeted therapy is changing rheumatoid arthritis (RA) management, but real-world data remain limited. This study aimed to describe real-world RA treatment patterns using data from a French national claims database. METHODS: This longitudinal study used the French Permanent Representative Sample (Echantillon Généraliste des Bénéficiaires) claims database. Patients with RA were identified between 2013 and 2017, with treatment patterns, persistence and adherence described. RESULTS: The study population included 2553 patients with RA. Disease-modifying antirheumatic drugs (DMARDs) were prescribed for 1512 (59.2%) patients, of whom 721 (47.6%) did not require discontinuation or treatment switch. There were 377 (24.9%) treatment discontinuations and 114 patients (7.5%) switched to a targeted DMARD (biological and synthetic (Janus kinase inhibitor) DMARDs). Among the 2315 patients with RA in 2017, almost half (n=1102, 47.6%) were not treated with a DMARD. Most (85.7%) received symptomatic treatment (analgesics (81.0%), steroids (49.2%), non-steroidal anti-inflammatory drugs (39.5%)). Of the 1142 treatment initiations identified, 713 (62.4%) were conventional synthetic DMARDs (csDMARDs), with methotrexate being the most frequent (n=553, 48.45%). One-year persistence rates varied between 55.9% (49.2-62.0%) for tumour necrosis factor inhibitors, and 63.4% (59.6-67.0%) for csDMARDs. Treatment adherence, assessed through medication possession ratio, varied between 71.9% and 90.8%, with ≥80% being the adherence cut-off. Almost half of DMARD initiations were associated with long-term (>6 months), high-dose oral steroid use (~7 mg/day prednisone equivalent). CONCLUSION: Despite a diverse therapeutic arsenal, there remains a medical need that is not covered by current RA management, which is frequently compensated for by overprescription of steroids.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Gaujoux-Viala C, Bergmann JF, Goguillot M, et al. Suboptimal management of rheumatoid arthritis in France: a real-world study based on data from the French National Health Data System. RMD Open. 2023. PMID: 37914177. doi:10.1136/rmdopen-2023-003075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。